WaveMan
WaveMan · Company
IMCR · Immunocore Holdings Plc
> Search tickers & screens ⌘K
LIVE
← All companies

IMCR Immunocore (IMCR) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001671927
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
78
13F, latest reported quarter

Immunocore insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Immunocore Holdings plc in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Jallal Bahija
CHIEF EXECUTIVE OFFICER
SELL
2026-02-19 SECtraded 2026-02-18
11,474
$371.2K
-4.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 93.0% of the 12,343 shares held after it.
  • 3 other insiders sold within 30 days.
  • 78 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER Jallal Bahija sold about $371.2K of IMCR on Feb 18, 2026; 3 other insiders sold within 30 days and 78 funds added in the latest 13F quarter.
GOLL JOHN
SVP, FINANCE & CAO
SELL
2026-02-19 SECtraded 2026-02-18
698
$22.6K
-4.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 106.9% of the 653 shares held after it.
  • 3 other insiders sold within 30 days.
  • 78 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, FINANCE & CAO GOLL JOHN sold about $22.6K of IMCR on Feb 18, 2026; 3 other insiders sold within 30 days and 78 funds added in the latest 13F quarter.
St Leger Tina Amber
CHIEF HR OFFICER
SELL
2026-02-19 SECtraded 2026-02-18
1,000
$32.4K
-4.3%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Apr 1, 2024.
  • The trade is 89.4% of the 1,119 shares held after it.
  • 3 other insiders sold within 30 days.
  • 78 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF HR OFFICER St Leger Tina Amber sold about $32.4K of IMCR on Feb 18, 2026; 3 other insiders sold within 30 days and 78 funds added in the latest 13F quarter.
Berman David M
HEAD OF R&D
SELL
2026-02-19 SECtraded 2026-02-18
5,965
$193.0K
-4.3%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Dec 5, 2025.
  • The trade is 101.8% of the 5,859 shares held after it.
  • 3 other insiders sold within 30 days.
  • 78 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: HEAD OF R&D Berman David M sold about $193.0K of IMCR on Feb 18, 2026; 3 other insiders sold within 30 days and 78 funds added in the latest 13F quarter.
Berman David M
HEAD OF R&D
SELL
2025-12-08 SECtraded 2025-12-05
572
$23.0K
-14.6%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Dec 4, 2025.
  • No other insider sold within 30 days.
  • 78 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: HEAD OF R&D Berman David M sold about $23.0K of IMCR on Dec 5, 2025; 78 funds added in the latest 13F quarter.
34 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 29 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
78 funds bought in last quarter
more than 59% of Pharma & Biotech
Revenue
+29.0% year over year
more than 70% of Pharma & Biotech
Margin
-8.9% net margin
more than 65% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
17.2% of the float short (float per yahoo 2026-10-26) · 20.7 days to cover · settled 2026-09-30
more than 86% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IMCR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-1.0%12M
-12%+1%+14%+27%2025-102025-122026-022026-042026-062026-082026-10 2025-11-26 · Berman David M sold $2.8M2025-12-04 · Berman David M sold $1.3M2025-11-25 · Berman David M sold $721.3K2026-02-18 · Jallal Bahija sold $371.2K2025-11-28 · Berman David M sold $221.3K2026-02-18 · Berman David M sold $193.0K2026-02-18 · St Leger Tina Amber sold $32.4K2025-12-05 · Berman David M sold $23.0K2026-02-18 · GOLL JOHN sold $22.6K2025-11-24 · Berman David M sold $4.0K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IMCR: institutional holders (13F)

13F holdings, latest reported quarter
WELLINGTON MANAGEMENT GROUP LLP
5,721,945 sh
$181.7M
RTW INVESTMENTS, LP
4,869,798 sh
$154.6M
FMR LLC
4,307,246 sh
$136.8M
PRIMECAP MANAGEMENT CO/CA/
3,638,241 sh
$115.5M
Bellevue Group AG
2,788,245 sh
$88.5M

Congress trades in IMCR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IMCR planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

IMCR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Archer Growth ETF
$312.2K position · as of 2026-05-31
2.4%
Virtus Biotech Etf
$1.6M position · as of 2026-07-31
1.6%
ALPS Medical Breakthroughs ETF
$1.5M position · as of 2026-05-31
0.9%
PRIMECAP Odyssey Aggressive Growth Fund
$37.6M position · as of 2026-07-31
0.5%
Tema Oncology ETF
$891.2K position · as of 2026-05-31
0.5%
THE HARTFORD HEALTHCARE FUND
$3.7M position · as of 2026-07-31
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Dr. Jallal
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$11.7M
$22.0M
$2.9M
+58%
-16%
2022
$8.0M
$51.3M
n/a
+32%
-20%
2021
$34.8M
$71.3M
n/a
-21%
-10%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 78 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

IMCR financials

Revenue growth
+29.0%
XBRL, annual
Net margin
-8.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$430.8M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-4.2%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$41.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
1.05x
long-term debt only, 2024-09-30 (21 months older than the period end); equity 2026-06-30
Cash flow to debt
-0.08x
TTM operating cash flow over long-term debt only, 2024-09-30 (21 months older than the period end)
Return on equity
-4.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-1.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-2.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.6B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2024-09-30 (21 months older than the period end), minus cash 2026-06-30
FCF yield
-2.6%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$400.0M$310.2M$249.4M$174.4M
Operating income-$45.4M-$70.5M-$59.6M-$51.7M
Net income-$35.5M-$51.1M-$55.3M-$52.5M
EPS (diluted)-0.71-1.02-1.13-1.15
Operating cash flow-$10.7M$26.1M$2.9M-$49.2M
Cash$467.7M$455.7M$442.6M$402.5M
SEC XBRL, fiscal years, as known on 2026-10-28

IMCR Stock Sonar score 5/7 axes

Find similar shapesCompare

IMCR ranks highest on profitability (81st percentile) and growth (70th), and lowest on financial health (44th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
81
Inputs
  • Return on equity-4.5% · 80 pct, sector of 545
  • Return on assets-1.6% · 80 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-2.5% · 84 pct, sector of 576
Financial health
44
Inputs
  • Debt to equity1.05x · 18 pct, sector of 352
  • Cash flow to debt-0.08x · 69 pct, sector of 371
Growth
70
Inputs
  • Revenue growth, YoY+29.0% · 70 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
59
Inputs
  • Funds adding, latest quarter78 · 59 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
47
Inputs
  • Short interest, % of float+17.2% · 20 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+6.7% · 73 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies